LifeTech Stent-Graft System Enters China’s Fast-Track Approval for Innovative Aortic Arch Devices

The latest announcement is out from LifeTech Scientific Corporation ( (HK:1302) ).

LifeTech Scientific has received confirmation from China’s National Medical Products Administration that its Concave Supra-arch Branched Stent-Graft System has been admitted into the special examination and approval procedure for innovative medical devices. Jointly developed with Fuwai Hospital’s Professor Shu Chang, the device is described as the world’s first integrated triple-branched reconstruction solution for complex aortic arch diseases, targeting aneurysms and penetrating ulcers with a minimally invasive approach that addresses long-standing anatomical and technical challenges in this high-risk field. Early clinical data from a First-in-Man feasibility study and ongoing multicenter registration trial show high technical success, low short-term mortality and stroke rates, and strong safety and efficacy indicators, positioning the product as a potentially significant advance in vascular surgery and reinforcing LifeTech’s standing as an innovator in China’s cardiovascular device market.

The most recent analyst rating on (HK:1302) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.

More about LifeTech Scientific Corporation

LifeTech Scientific Corporation is a medical device company focused on innovative cardiovascular and endovascular solutions, developing minimally invasive products for the treatment of complex vascular diseases. The group collaborates with leading clinical institutions in China to design specialized devices targeting technically challenging areas such as aortic arch interventions.

Average Trading Volume: 32,608,344

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$7.17B

For a thorough assessment of 1302 stock, go to TipRanks’ Stock Analysis page.